Abstract: This disclosure describes, in one aspect, a composition for intracellular delivery of a polypeptide. Generally, the composition includes a substrate that has a surface, a cleavable linker affixed to at least a portion of the surface, and a cargo polypeptide bound to the cleavable linker. In some embodiments, the cargo polypeptide can further include a targeting peptide. In another aspect, this disclosure describes a method for intracellular delivery of a polypeptide. Generally, the method includes administering to a subject any embodiments of the composition summarized above, and cleaving the cleavable linker, thereby releasing the cargo polypeptide from the substrate.

Abstract: This disclosure describes, in one aspect, a composition for intracellular delivery of a polypeptide. Generally, the composition includes a substrate that has a surface, a cleavable linker affixed to at least a portion of the surface, and a cargo polypeptide bound to the cleavable linker. In some embodiments, the cargo polypeptide can further include a targeting peptide. In another aspect, this disclosure describes a method for intracellular delivery of a polypeptide. Generally, the method includes administering to a subject any embodiments of the composition summarized above, and cleaving the cleavable linker, thereby releasing the cargo polypeptide from the substrate.

Abstract: A composition including a C terminal region having residues corresponding to a peptide identified by PDB ID: 1RG3; an N terminal region having residues corresponding to a peptide identified by PDB ID: 1RG4; and a disulfide linkage between the residues near the C terminal region and the N terminal region. A composition including an exogenous peptide comprising amino acid residues comprising a C terminal region; amino acid residues comprising an N terminal region; a helix-loop-helix conformation between the residues comprising the C terminal region and the residues including the N terminal region; and at least one disulfide linkage between the residues comprising the C terminal region and the residues including N terminal region, wherein the residues including the C terminal region and the residues comprising the N terminal region have an amphiphatic property, and wherein the peptide has an a biological activity comparable to native surfactant protein SP-B.

Abstract: A therapeutic pharmaceutical composition for the treatment of respiratory disease is disclosed, including particularly Respiratory Distress Syndrome (RDS). The composition is comprised of a synthetic dimer of an N-terminal fragment of Surfactant Protein B (SP-B) that advantageously mimics the functional activity of native human Surfactant Protein B, and to therapeutic methods of administration of such pharmaceutical compositions.

Abstract: A therapeutic pharmaceutical composition for the treatment of respiratory disease is disclosed, including particularly Respiratory Distress Syndrome (RDS). The composition is comprised of a synthetic dimer of an N-terminal fragment of Surfactant Protein B (SP-B) that advantageously mimics the functional activity of native human Surfactant Protein B, and to therapeutic methods of administration of such pharmaceutical compositions.

Abstract: The present invention provides compositions and methods of preparing a bilayer structure for encapsulating multiple containment units. These containment units can contain therapeutic, diagnostic agents or imaging agents that can be released through the bilayer structure. A suitable example of such a containment unit is a unilamellar or multilamellar vesicle.

Abstract: The present invention provides compositions and methods of preparing a bilayer structure for encapsulating multiple containment units. These containment units can contain therapeutic, diagnostic agents or imaging agents that can be released through the bilayer structure. A suitable example of such a containment unit is a unilamellar or multilamellar vesicle.

Abstract: The present invention provides a bilayer structure for encapsulating multiple containment units. These containment units can attach or contain therapeutic or diagnostic agents that can be released through the bilayer structure. A suitable example of such a containment unit is a unilamellar or multilamellar vesicle.

Abstract: The present invention provides a bilayer structure for encapsulating multiple containment units. These containment units can attach or contain therapeutic or diagnostic agents that can be released through the bilayer structure. A suitable example of such a containment unit is a unilamellar or multilamellar vesicle.